Preformulation Studies of Cefixime for Dispersible Tablets Delivery System Development

A recent study explored the preformulation, formulation, and evaluation of Cefixime (CFX) dispersible tablets aimed at improving the antibiotic’s bioavailability. Cefixime, a third-generation cephalosporin effective against Bacteroides species, acts by inhibiting penicillin-binding proteins and disrupting peptidoglycan synthesis, thereby damaging the bacterial cell wall.

During the preformulation stage, researchers conducted extensive drug–excipient compatibility studies using analytical methods such as HPLC, FTIR spectroscopy, and melting point analysis. Precompression parameters and powder flow properties were also evaluated to ensure formulation feasibility.

The results indicated that Cefixime was compatible with most selected excipients, supporting its suitability for dispersible tablet formulation. However, incompatibility was observed with Tween® 80 and sodium saccharin.

Researchers concluded that these findings provide critical insights for formulation scientists in the development of Advanced Drug Delivery Systems (ADDS) and underscore the importance of thorough preformulation studies in optimizing antibiotic formulations.